Cystic Fibrosis Market on Track for Major Expansion by 2034, According to DelveInsight | Insmed, AstraZeneca, Zambion, The Marcus Foundation, Chiesi Farmaceutici, SolAeroMed

Posted on
by

Cystic Fibrosis Market on Track for Major Expansion by 2034, According to DelveInsight | Insmed, AstraZeneca, Zambion, The Marcus Foundation, Chiesi Farmaceutici, SolAeroMed
The Key Cystic Fibrosis Companies in the market include – Vertex Pharmaceuticals, Verona Pharmaceuticals, Boehringer Ingelheim, Zambon, Insmed, AstraZeneca, Zambion, The Marcus Foundation, Inc., Chiesi Farmaceutici S.p.A., SolAeroMed Inc., Zambon SpA, Boehringer Ingelheim, Renovion, Inc., Novartis, Alaxia SAS, and others.

 

DelveInsight’s “Cystic Fibrosis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Cystic Fibrosis, historical and forecasted epidemiology as well as the Cystic Fibrosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Cystic Fibrosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Cystic Fibrosis Market Forecast

 

Some of the key facts of the Cystic Fibrosis Market Report: 

  • The Cystic Fibrosis market size was valued approximately ~USD 18,743 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

  • In November 2024, Spirovant Sciences, a clinical-stage gene therapy company focused on inherited respiratory diseases, announced that the first patient has been treated in its SAAVe Phase 1/2 clinical trial evaluating SP-101 combined with Augmenter for cystic fibrosis. Administered via inhalation, SP-101 is an investigational recombinant adeno-associated virus (AAV) gene therapy optimized for its affinity to human airway epithelial cells. The selected augmenter, doxorubicin, enhances the expression of the functional CFTR transgene to levels expected to deliver significant clinical benefits.

  • In June 2024, 4DMT plans to initiate the Phase II dose expansion phase of its AEROW clinical trial following positive interim results for its gene therapy, 4D-710. The therapy, which combines an AAV vector with a CFTR transgene, is being tested in patients with cystic fibrosis (CF). It is specifically designed for individuals who are either ineligible for or unable to tolerate CFTR modulator therapies.

  • In 2023, the cystic fibrosis market size in the EU4 and the UK was approximately USD 7,395 million, representing about 39.4% of the total market size across the 7MM.

  • Among the EU4 and the UK, Germany has the largest cystic fibrosis market size, estimated at around USD 1,977 million, followed by Italy and France with approximately USD 1,505 million and USD 1,436 million, respectively. These figures are anticipated to fluctuate during the forecast period.

  • According to DelveInsight’s analysis, the estimated total number of diagnosed prevalent cases of cystic fibrosis in the 7MM was around 67,897 in 2023. The implementation of expanded genetic testing will help identify more individuals with cystic fibrosis, leading to an overall rise in reported cases.

  • In 2023, the US had the highest number of diagnosed prevalent cases of cystic fibrosis among the 7MM, with roughly 33,391 cases. This number is projected to rise during the forecast period from 2024 to 2034.

  • Among the EU4 and the UK, the UK reported the highest number of diagnosed prevalent cases of cystic fibrosis, totaling nearly 11,275 cases. It was followed by France and Germany, which had approximately 7,506 and 7,043 diagnosed prevalent cases, respectively.

  • According to DelveInsight’s analysis, there were more diagnosed prevalent cases of cystic fibrosis in males than in females. In 2023, approximately 17,363 males and 16,027 females were diagnosed with prevalent cases of cystic fibrosis in the US.

  • In the epidemiological model of cystic fibrosis, cases are divided into two age groups: children and adults. In the EU4 and the UK, a higher percentage of cases are reported among adults, with around 14,651 cases in children and 19,801 cases in adults.

  • Key Cystic Fibrosis Companies: Vertex Pharmaceuticals, Verona Pharmaceuticals, Boehringer Ingelheim, Zambon, Insmed, AstraZeneca, Zambion, The Marcus Foundation, Inc., Chiesi Farmaceutici S.p.A., SolAeroMed Inc., Zambon SpA, Boehringer Ingelheim, Renovion, Inc., Novartis, Alaxia SAS, and others

  • Key Cystic Fibrosis Therapies: SYMDEKO, KALYDECO, VX-121/TEZ/ VX-561, Ensifentrine, CMS I-neb, BI 1291583, Brensocatib, Colistimethatesodium, Trikafta, CHF 6333, S-1226, CMS, BI 1323495, ARINA-1, TIP, ALX-009, and others

  • The Cystic Fibrosis epidemiology based on gender analyzed that in the US, females diagnosed with NCFB are higher in number than males.

  • The Cystic Fibrosis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Cystic Fibrosis pipeline products will significantly revolutionize the Cystic Fibrosis market dynamics.

 

Cystic Fibrosis Overview

Cystic Fibrosis (NCFB) is a chronic respiratory condition characterized by the abnormal widening and inflammation of the bronchial tubes in the lungs. Unlike cystic fibrosis (CF)-related bronchiectasis, which is caused by genetic mutations affecting the production of mucus, NCFB occurs in individuals without CF.

 

Get a Free sample for the Cystic Fibrosis Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/cystic-fibrosis-market

 

Cystic Fibrosis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Cystic Fibrosis Epidemiology Segmentation:

The Cystic Fibrosis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Cystic Fibrosis

  • Prevalent Cases of Cystic Fibrosis by severity

  • Gender-specific Prevalence of Cystic Fibrosis

  • Diagnosed Cases of Episodic and Chronic Cystic Fibrosis

 

Download the report to understand which factors are driving Cystic Fibrosis epidemiology trends @ Cystic Fibrosis Epidemiology Forecast

 

Cystic Fibrosis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cystic Fibrosis market or expected to get launched during the study period. The analysis covers Cystic Fibrosis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Cystic Fibrosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Cystic Fibrosis Therapies and Key Companies

  • SYMDEKO: Vertex Pharmaceuticals

  • KALYDECO: Vertex Pharmaceuticals

  • VX-121/TEZ/ VX-561: Vertex Pharmaceuticals

  • Ensifentrine: Verona Pharmaceuticals

  • CMS I-neb: Zambon

  • BI 1291583: Boehringer Ingelheim

  • Brensocatib: Insmed/ AstraZeneca

  • Colistimethatesodium: Zambion

  • Trikafta: The Marcus Foundation, Inc.

  • CHF 6333: Chiesi Farmaceutici S.p.A.

  • S-1226: SolAeroMed Inc.

  • CMS: Zambon SpA

  • BI 1323495: Boehringer Ingelheim

  • ARINA-1: Renovion, Inc.

  • TIP: Novartis

  • ALX-009: Alaxia SAS

 

Discover more about therapies set to grab major Cystic Fibrosis market share @ Cystic Fibrosis Treatment Landscape

 

Cystic Fibrosis Market Strengths

  • Increasing disease prevalence due to better detection rate with advanced imaging techniques and improved awareness.

  • An improved understanding of disease pathophysiology has improved diagnosis and is useful in determining novel target molecules for treatment development.

 

Cystic Fibrosis Market Opportunities

  • Large, positive, randomized controlled trials are necessary to set the standard of care for bronchiectasis patients.

  • Vaccines and monoclonal antibodies, though partially useful, there is a need for evidence-based studies to use for the prevention of PA chronic colonization in bronchiectasis patients.

 

Scope of the Cystic Fibrosis Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Cystic Fibrosis Companies: Vertex Pharmaceuticals, Verona Pharmaceuticals, Boehringer Ingelheim, Zambon, Insmed, AstraZeneca, Zambion, The Marcus Foundation, Inc., Chiesi Farmaceutici S.p.A., SolAeroMed Inc., Zambon SpA, Boehringer Ingelheim, Renovion, Inc., Novartis, Alaxia SAS, and others

  • Key Cystic Fibrosis Therapies: SYMDEKO, KALYDECO, VX-121/TEZ/ VX-561, Ensifentrine, CMS I-neb, BI 1291583, Brensocatib, Colistimethatesodium, Trikafta, CHF 6333, S-1226, CMS, BI 1323495, ARINA-1, TIP, ALX-009, and others

  • Cystic Fibrosis Therapeutic Assessment: Cystic Fibrosis current marketed and Cystic Fibrosis emerging therapies

  • Cystic Fibrosis Market Dynamics: Cystic Fibrosis market drivers and Cystic Fibrosis market barriers 

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Cystic Fibrosis Unmet Needs, KOL’s views, Analyst’s views, Cystic Fibrosis Market Access and Reimbursement 

 

To know more about Cystic Fibrosis companies working in the treatment market, visit @ Cystic Fibrosis Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Cystic Fibrosis Market Report Introduction

2. Executive Summary for Cystic Fibrosis

3. SWOT analysis of Cystic Fibrosis

4. Cystic Fibrosis Patient Share (%) Overview at a Glance

5. Cystic Fibrosis Market Overview at a Glance

6. Cystic Fibrosis Disease Background and Overview

7. Cystic Fibrosis Epidemiology and Patient Population

8. Country-Specific Patient Population of Cystic Fibrosis 

9. Cystic Fibrosis Current Treatment and Medical Practices

10. Cystic Fibrosis Unmet Needs

11. Cystic Fibrosis Emerging Therapies

12. Cystic Fibrosis Market Outlook

13. Country-Wise Cystic Fibrosis Market Analysis (2020–2034)

14. Cystic Fibrosis Market Access and Reimbursement of Therapies

15. Cystic Fibrosis Market Drivers

16. Cystic Fibrosis Market Barriers

17.  Cystic Fibrosis Appendix

18. Cystic Fibrosis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/